NCT01486797已完成2 期
A Multi-center, Open Label, Uncontrolled, Phase IIA Clinical Trial Evaluating the Safety and Efficacy of NOX A12 in Combination With a Background Therapy of Bendamustine and Rituximab (BR) in Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)
TME Pharma AG17 个研究点 分布在 4 个国家目标入组 28 人开始时间: 2012年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 28
- 试验地点
- 17
- 主要终点
- Safety and tolerability of NOX A12 alone and in combination with BR.
研究概览
简要总结
The purpose of this study is to evaluate the safety and efficacy of NOX A12 in combination with a background therapy of bendamustine and rituximab (BR) chemotherapy in previously treated patients with chronic lymphocytic leukemia (CLL).
详细描述
CLL cells express high levels of CXCR4 chemokine receptors, which cause leukemia cell migration and adhesion to stromal cells secreting the CXCR4 ligand, CXCL12 (or stromal-derived-factor 1, SDF-1). NOX A12 is a specific CXCL12 antagonist and may improve BR therapy by disrupting CXCR4-CXCL12 interactions, thereby mobilizing CLL cells from protective tissue microenvironments to the blood. Furthermore, SDF-1 inhibition may alter the activation status of CLL cells, thereby triggering apoptosis or sensitization of CLL cells towards chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of B-cell CLL
- •Relapsed, bendamustine-sensitive (at least partial response with a duration of at least six months) or bendamustine-naive patients after at least one but not more than 3 prior treatments of their disease.
- •CLL in need of treatment (Binet C or A/B with active disease) according to Hallek et al. 2008
- •Subject must have measurable disease according to NCI-WG criteria (for details see Hallek M, Blood 2008; 111: 5446-5456).
- •Pre-study WHO performance status ≤ 2 and modified cumulative illness rating score (CIRS) of less than
- •Signed, written informed consent.
- •Men and women of reproductive potential must agree to follow accepted birth control methods during treatment and for 3 months after completion of treatment.
- •Acceptable liver function: Bilirubin ≤ 1.5 x upper limit of normal (ULN) at screening, AST (SGOT) and/or ALT (SGPT) ≤ 2.5 x ULN.
- •Acceptable hematologic status: Platelet count ≥ 75 x 109/L, ANC > 0.75x109/L.
- •Acceptable renal function: Serum creatinine ≤1.5 ULN and/or calculated creatinine clearance (Cockroft-Gault Formula) ≥ 50 mL/min
- •Male or female, age ≥ 18
- •No clinically significant abnormalities of liver volume, liver hemodynamics or elasticity, measured by abdominal ultrasound.
排除标准
- •Relapse of B-cell CLL within 12 months after last chemotherapy.
- •Subjects who have progressed to more aggressive B-cell cancers such as Richter's syndrome.
- •CLL with documented loss of the short arm of chromosome 17 (17p-) associated with the loss of p
- •The subject has a history of or is clinically suspicious for cancer-related Central Nervous System disease.
- •Patients at risk of hemostasis or spleen rupture.
- •Autoimmune hemolytic anemia.
- •Prior allogeneic stem cell transplant (alloSCT) or patients who are considered to be candidates for allo SCT as assessed by their treating physician
- •Patient has a history of other active malignancies within three years prior to study entry, with the exception of: adequately treated in situ carcinoma of the cervix uteri; basal or squamous cell carcinoma of the skin; in situ carcinoma of the bladder; previous malignancy confined and surgically resected with curative intent.
- •The patient exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to: uncontrolled systemic infection (viral, bacterial, or fungal); diagnosis of fever and neutropenia within 1 week prior to study drug administration.
- •Female subject is pregnant or breast-feeding.
- •Known infection with HIV, active Hepatitis B or Hepatitis C.
- •The patient has a history of prior toxicity from bendamustine or rituximab that resulted in permanent discontinuation of treatments.
- •Treatment with other investigational drugs, or participation in another clinical trial within 30 days prior to study drug administration.
- •Uncontrolled hypertension (defined as systolic blood pressure (BP) > 160 mm Hg or diastolic BP > 100 mm Hg).
- •Myocardial infarction or unstable angina within the past 6 months prior to study drug administration.
- •Systemic illnesses or other severe concurrent disease including alcoholism which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and efficacy of the investigational treatments.
- •Known or suspected of not being able to comply with the trial protocol.
- •Having been previously enrolled in this clinical trial.
- •Known hypersensitivity to rituximab or to any of the excipients or to murine proteins
- •History of recurring or chronic infections or underlying conditions which may further predispose patients to serious infection.
- •Known hypersensitivity to bendamustine or to mannitol.
- •Invasive surgery within 30 days prior to study drug administration.
研究组 & 干预措施
NOX-A12
Experimental
干预措施: NOX-A12 (Drug)
结局指标
主要结局
Safety and tolerability of NOX A12 alone and in combination with BR.
时间窗: 30 months
The safety evaluation will be based on the following assessments: * adverse events * vital signs * 12 lead ECGs * laboratory parameters * immunogenicity
Complete remission (CR) rate
时间窗: 6 months
Assessment of the complete remission rate after cycle 3 and 6 will be the primary efficacy endpoint. The 1996 NCI-WG criteria which have been updated in 2008 will be applied.
次要结局
- Pharmacodynamics of NOX-A12 alone and in combination with BR(6 months)
- Overall response rate (ORR = CR + PR)(6 months)
- Progression free survival (PFS)(30 months)
- Pharmacokinetics of NOX-A12 alone and in combination with BR(10 time points over 6 months)
- Event free survival (EFS)(30 months)
- Time to progression (TTP)(30 months)
- Duration of response (DOR)(30 months)
- Overall survival (OS)(30 months)
研究者
研究点 (17)
Loading locations...
相似试验
已完成
2 期
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple MyelomaMultiple MyelomaNCT01521533TME Pharma AG28
已完成
2 期
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With CancerAnemia of Chronic DiseaseNCT01691040TME Pharma AG12
已完成
2 期
NOX-100 for Preventing Hypotension During HemodialysisHypotensionNCT01672008Medinox, Inc.62
已完成
3 期
Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With PresbyopiaPresbyopiaNCT05646719Ocuphire Pharma, Inc.333
终止
2 期
Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's DiseaseCrohn's DiseaseNCT00130390Romark Laboratories L.C.98